128 related articles for article (PubMed ID: 11963641)
21. Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine.
Dorababu M; Nishimura A; Prabha T; Naruhashi K; Sugioka N; Takada K; Shibata N
Biomed Pharmacother; 2009 Nov; 63(9):697-702. PubMed ID: 19819100
[TBL] [Abstract][Full Text] [Related]
22. Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions.
Uesawa Y; Takeuchi T; Mohri K
Curr Pharm Biotechnol; 2012 Jul; 13(9):1705-17. PubMed ID: 22039822
[TBL] [Abstract][Full Text] [Related]
23. [Drug information about lercanidipine. A new dihydropyridine calcium antagonist for the treatment of arterial hypertension].
Christensen KL
Ugeskr Laeger; 2005 Jan; 167(2):153-5. PubMed ID: 15697124
[No Abstract] [Full Text] [Related]
24. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers.
Glesby MJ; Aberg JA; Kendall MA; Fichtenbaum CJ; Hafner R; Hall S; Grosskopf N; Zolopa AR; Gerber JG;
Clin Pharmacol Ther; 2005 Aug; 78(2):143-53. PubMed ID: 16084849
[TBL] [Abstract][Full Text] [Related]
25. Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81.
Zhang JG; Dehal SS; Ho T; Johnson J; Chandler C; Blanchard AP; Clark RJ; Crespi CL; Stresser DM; Wong J
Drug Metab Dispos; 2006 May; 34(5):734-7. PubMed ID: 16501008
[TBL] [Abstract][Full Text] [Related]
26. MDR- and CYP3A4-mediated drug-drug interactions.
Pal D; Mitra AK
J Neuroimmune Pharmacol; 2006 Sep; 1(3):323-39. PubMed ID: 18040809
[TBL] [Abstract][Full Text] [Related]
27. Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues.
Angelico P; Guarneri L; Leonardi A; Testa R
J Pharm Pharmacol; 1999 Jun; 51(6):709-14. PubMed ID: 10454048
[TBL] [Abstract][Full Text] [Related]
28. Relationship between lipophilicities of 1,4-dihydropyridine derivatives and pharmacokinetic interaction strengths with grapefruit juice.
Uesawa Y; Mohri K
Yakugaku Zasshi; 2008 Jan; 128(1):117-22. PubMed ID: 18176062
[TBL] [Abstract][Full Text] [Related]
29. Dietary effects on drug metabolism and transport.
Harris RZ; Jang GR; Tsunoda S
Clin Pharmacokinet; 2003; 42(13):1071-88. PubMed ID: 14531721
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic interactions with rifampicin : clinical relevance.
Niemi M; Backman JT; Fromm MF; Neuvonen PJ; Kivistö KT
Clin Pharmacokinet; 2003; 42(9):819-50. PubMed ID: 12882588
[TBL] [Abstract][Full Text] [Related]
31. Interaction profile and tolerability of barnidipine.
Beudeker HJ; van der Velden JW; van der Aar EM
Int J Clin Pract Suppl; 2000 Nov; (114):36-40. PubMed ID: 11221293
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.
Pea F; Furlanut M
Clin Pharmacokinet; 2001; 40(11):833-68. PubMed ID: 11735605
[TBL] [Abstract][Full Text] [Related]
33. Dihydropyridines are not substitutable without careful monitoring.
S Afr Med J; 2002 Aug; 92(8):596. PubMed ID: 12244612
[No Abstract] [Full Text] [Related]
34. Stereoselective pharmacokinetics of dihydropyridine calcium antagonists.
Tokuma Y; Noguchi H
J Chromatogr A; 1995 Mar; 694(1):181-93. PubMed ID: 7719464
[TBL] [Abstract][Full Text] [Related]
35. A proposal for a pharmacokinetic interaction significance classification system (PISCS) based on predicted drug exposure changes and its potential application to alert classifications in product labelling.
Hisaka A; Kusama M; Ohno Y; Sugiyama Y; Suzuki H
Clin Pharmacokinet; 2009; 48(10):653-66. PubMed ID: 19743887
[TBL] [Abstract][Full Text] [Related]
36. A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling.
Fuhr LM; Marok FZ; Mees M; Mahfoud F; Selzer D; Lehr T
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890369
[TBL] [Abstract][Full Text] [Related]
37. Calcium channel blocker-clarithromycin drug interaction did not increase the risk of nonvertebral fracture: a population-based study.
Fraser LA; Shariff SZ; McArthur E; Naylor KL; Garg AX
Ann Pharmacother; 2015 Feb; 49(2):185-8. PubMed ID: 25429094
[TBL] [Abstract][Full Text] [Related]
38. Clinical hypotension with co-prescription of macrolide antibiotics and calcium-channel blockers in haemodialysis patients: a retrospective chart review.
Hiremath S; Ruzicka M; Nagaraju SP; McCormick BB
Drug Saf; 2013 Oct; 36(10):989-93. PubMed ID: 23873482
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy.
Wang ZY; Chen M; Zhu LL; Yu LS; Zeng S; Xiang MX; Zhou Q
Ther Clin Risk Manag; 2015; 11():449-67. PubMed ID: 25848291
[TBL] [Abstract][Full Text] [Related]
40. [Dihydropyridines from the first to the fourth generation: better effects and safety].
Aouam K; Berdeaux A
Therapie; 2003; 58(4):333-9. PubMed ID: 14679672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
